Osteoporosis is characterized by low bone mass and deterioration of bone micro-architecture associated with increased bone fragility and susceptibility to fracture. In 2005 the incidence of osteoporotic fracture in the US was over two million, at a cost of nearly $17 billion. By 2025, annual fractures and costs are projected to rise by almost 50%, making this a major healthcare priority.
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development, but paradoxically also results in short stature due to premature closure of the epiphyseal growth plates. 9 Changes in thyroid status in adults affect the bone re-modeling cycle. Hypothyroidism reduces bone turnover and prolongs the re-modeling cycle, 10 and increased mineralization in the formation phase can lead to elevated bone mineral density. Hyperthyroidism increases bone turnover, with increases in both osteoclast and osteoblast activities. 10 As a result, the bone re-modeling cycle is shortened, although all phases of the cycle are not affected equally. While the duration of the resorption phase is largely unaltered, the duration of the formation phase is reduced significantly.
This leads to a failure to replace resorbed bone completely, resulting in net loss of about 10% of mineralized bone per cycle. 4 Hyperthyroidismassociated bone loss has long been attributed to elevated levels of thyroid hormones. 6 However, more recently a role for TSH as a direct inhibitor of bone turnover has been suggested by studies analyzing skeletal abnormalities in TSH receptor knockout mice. 11 The relative importance of thyroid hormones and TSH in the physiological control of bone turnover remains controversial. This is because the normal reciprocal relationship between thyroid hormones and TSH, which is maintained by the HPT axis, makes it difficult to separate the opposing skeletal effects of thyroid hormones and TSH in vivo, and further studies are required.
Mechanisms of Bone Loss in Hyperthyroidism
A number of studies in genetically modified mice have advanced our understanding of the actions of thyroid hormones on bone and the mechanisms of accelerated bone loss in hyperthyroidism. TRα 0/0 mice, which lack all TRα isoforms, are euthyroid with normal T4 and TSH levels. regulates osteoblast proliferation and function directly, but it is currently unclear whether osteoclast proliferation and function is regulated directly by T3 or via osteoblast-mediated effects. 3 While these findings suggest that skeletal hyperthyroidism results from elevated T3 levels rather than low TSH levels, a direct role for TSH as a negative regulator of bone turnover has been suggested. 11 The TSH receptor (TSHR), a G-protein-coupled receptor, is expressed in several cell types and was shown to be expressed in osteoclasts and osteoblasts in vitro. 11 TSHR knockout mice (TSHR -/-) have congenital hypothyroidism, with undetectable levels of thyroid hormone and grossly elevated TSH levels. 11 The mice had evidence of high-bone-turnover osteoporosis, and the authors postulated that TSH directly inhibits bone re-modeling.
However, it has been noted that thyroid hormone replacement was instituted in these mice at post-natal day 21, although the normal maximum growth velocity in mice is seen at two weeks of age, when T3
and T4 levels reach their physiological peak. 12 It is possible that the accelerated bone re-modeling noted in TSHR -/-mice reflects 'catch-up' growth due to delayed thyroid hormone replacement. 3, 12 In order to delineate the relative importance of T3 and TSH in bone further, the skeletal phenotypes of two mouse models of congenital hypothyroidism were compared. 13 Pax8 null mice (Pax8 -/-) lack a transcription factor required for thyroid follicular development. [20] [21] [22] [23] Even though the length of
follow-up and degree of improvement in BMD varied between studies, BMD did not return to normal in any of them. Despite this, a crosssectional study of 164 women found BMD to be significantly reduced in patients in the first three years following diagnosis of thyrotoxicosis. 24 After this interval, however, BMD did not differ significantly compared with control subjects. It is clear that BMD improves after treatment of hyperthyroidism, although there are conflicting data regarding whether recovery is full following restoration of euthyroidism.
A more important clinical end-point to consider is the risk for fracture in patients with hyperthyroidism. Studies published in the 1990s revealed an association between hyperthyroidism and an increased risk for hip 25, 26 and foot 27 fracture in post-menopausal women. Only one study demonstrated no increased risk for fracture in women with a history of hyperthyroidism; however, individuals in that study were found to have an earlier occurrence of first fracture compared with normal subjects with no prior history of thyrotoxicosis. 28 A large retrospective, populationbased study of 7,209 patients treated with radioactive iodine for hyperthyroidism demonstrated an increased risk for death due to fracture of the femur, with a 2.9-fold increased standardized mortality ratio. There are fewer data on the effect of sub-clinical hyperthyroidism on BMD in pre-menopausal women, although a few studies have shown no effect. 32, 35, 38 One study showed a decrease in BMD in femoral neck and phalanges but not lumbar spine. 33 The effect of sub-clinical hyperthyroidism on BMD in men has not been investigated adequately.
However, a recent study showed a significant reduction in BMD at the ultra-distal forearm in men with a TSH level below the 25th percentile. 39 Post-menopausal women with endogenous sub-clinical hyperthyroidism appear to be at risk for bone loss, most consistently in the femoral neck, but also in the lumbar spine. Most data suggest that pre-menopausal women do not share this risk. While the risk for fracture due to subclinical hyperthyroidism is less well defined, a prospective cohort study in post-menopausal women addressed this issue. 40 The authors showed that a suppressed TSH, from any cause, led to a 3.6-fold increased risk for hip fracture and a 4.5-fold increased risk for vertebral fracture.
A similar scenario was also seen in studies analyzing the effect on BMD of suppressive doses of thyroxine in the treatment of differentiated thyroid cancer. A recent systematic review selected and analyzed 21 studies. 41 The authors concluded that while no increased risk was seen in men or pre-menopausal women, post-menopausal women on suppressive doses of thyroxine were at risk for reduced bone density. This conclusion correlated with the findings of previous reviews. 6, 42 It is recommended that post-menopausal women with thyroid cancer at high risk for recurrence, who require long-term TSH suppression with thyroxine, be monitored closely for osteoporosis. 43 
